Long-term comparative outcomes in relapse activity and disability progression among anti-CD20 therapies in relapsing multiple sclerosis: An unanchored matching-adjusted indirect comparison. (PubMed, Mult Scler Relat Disord) - Oct 6, 2026 - "These findings suggest directionally favorable long-term outcomes with ublituximab compared with the other two comparators. These findings should be interpreted carefully within the assumptions and inherent limitations of the unanchored MAIC approach."
Journal • CNS Disorders • Multiple Sclerosis
|
|
Amir Ansaripour; Andreas B Schmitt; Bassem Yamout; Diego Centonze; Gary Cutter; Hans Peter Hartung; Hari Miskin; Jérôme De Seze; Klaus Schmierer; Krzysztof Selmaj; Mehdi Javanbakht; Michael Barnett; Nikolaos Grigoriadis; Ralf Gold
|